Kiai Parsa purchased $68K of MED (indirect holdings)

Kiai Parsa purchased 5,557 indirectly-held shares of MEDIFAST INC (MED) at $12.24 across 2 trades on 2026-10-28.

Original reporting
SEC EDGAR · Kiai Parsa
Published Oct 30, 2026, 4:56 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 4:56 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MED
Bullish
high confidence
Mentioned
$MED
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MEDBullishLow
01

Why it matters

The director's purchase may be interpreted as a vote of confidence, but the modest $68K size limits market impact.

02

Market read

Insider buying is a modest positive signal for MED, unlikely to move the broader market.

03

What to watch

Potential upcoming corporate actions or earnings that prompted the insider purchase.

Relevance 4/10Novelty 4/10Timing: post-filing today

Background

Form 4 filings disclose insider transactions and are considered primary sources of material information.

Company-level read

Ticker impact

$MEDBullishHigh confidence
Context

Director Kiai Parsa bought 5,557 shares of Medifast at $12.24 each, increasing his stake to 20,428 shares.

Expected impact

potential modest upward pressure as market absorbs insider buying

Evidence & confidence

The purchase is a primary Form 4 filing, indicating new material information about insider confidence.

Market effects

Minimal impact on the health and nutrition sector; insider activity is company-specific.

Limited to US markets where MED trades.

Low; does not affect broader market trends.

Counterpoint

The small size of the purchase may be insignificant and could be routine portfolio rebalancing.

Key entities

  • Kiai Parsa

    Director of Medifast who purchased shares.

  • Medifast Inc

    US-listed health and nutrition company (ticker MED).

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MEDMed

5 insightful analyst questions from Medifast’s Q3 earnings call

Medifast's Q3 revenue exceeded expectations but declined year-over-year. Management cited the Trilogy brand's success and improved coach productivity. Analysts questioned coach engagement, competition with GLP-1 medications, and cost reduction. The stock is trading at $12.50. Key focus areas include Trilogy adoption, coach productivity, and cost efficiencies.

$MEDHigh

Why Medifast (MED) stock is trading up today

Medifast (MED) shares rose 6.2% after Q3 results beat expectations, with adjusted EBITDA of $1.9M. CEO Nick Johnson highlighted new product launches and guidance for Q4 revenue of $55M-$75M. Full-year revenue is expected at $280M-$300M, with a GAAP loss of $1.80-$2.05 per share.

$MEDMed

Medifast Inc (MED) (Q3 2026) Earnings Call Highlights: Revenue Stabilizes Near $75 Million

Medifast Inc (MED) reported Q3 2026 revenue of $72M, down 19.4% YoY, with revenue stabilizing near $75M for four quarters. CEO Nicholas Johnson highlighted high engagement and productivity among coaches, despite a decline in active coach numbers. The company expects continued productivity growth and cost efficiencies. Q4 revenue guidance is $55M-$75M, with EPS of $0-$0.25. Medifast has $172.5M in cash and no debt, with a target of profitability in Q4 2026.

$MEDMed

Medifast, Inc. Q3 2026 Earnings Call Summary

Medifast (MED) reported a 19.4% revenue decline in Q3 2026, attributing it to lower active coach counts due to GLP-1 medication adoption. The company is transitioning to a metabolic health system called Trilogy and implementing cost-cutting measures. Q4 2026 revenue is expected between $55M and $75M, with a focus on profitability and long-term growth. Management sees GLP-1s as a catalyst for consumer interest rather than a direct threat.

$MEDMed

What Medifast (MED) Said on Its Q3 Earnings Call

Medifast (MED) reported a Q3 operating loss of $19.4M, including restructuring charges. The company introduced new products and highlighted GLP-1 medications' impact on client conversations. Medifast forecasts Q4 revenue of $55M-$75M and full-year 2026 revenue of $280M-$300M, aiming for profitability in Q4.